Search research articles
Contact Us
Filters
Showing results (101-110 of 574) with videos related to
Page
of 58
Sort By:
Journal of Clinical Microbiology
|
November 28, 2014
A case of IMP-4-, OXA-421-, OXA-96-, and CARB-2-producing Acinetobacter pittii sequence type 119 in Australia
Witchuda Kamolvit, Petra Derrington, David L Paterson, et al.
The Journal of Antimicrobial Chemotherapy
|
December 17, 2020
An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa
Burcu Isler, Patrick Harris, Adam G Stewart, et al.
Infectious Diseases (London, England)
|
March 6, 2024
Host response signature trends in bacteraemia - authors' response
Anna Maria Peri, Patrick N A Harris, David L Paterson
Antimicrobial Agents and Chemotherapy
|
October 17, 2018
New Treatment Options against Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infections
Burcu Isler, Yohei Doi, Robert A Bonomo, et al.
The American Journal of Tropical Medicine and Hygiene
|
October 14, 2005
Leptospirosis after recreational exposure to water in the Yaeyama islands, Japan
Masashi Narita, Shigeki Fujitani, David A Haake, et al.
Critical Care Medicine
|
July 4, 2008
Antibiotic resistance--what's dosing got to do with it?
Jason A Roberts, Peter Kruger, David L Paterson, et al.
International Journal of Antimicrobial Agents
|
September 18, 2013
Ampicillin/sulbactam: its potential use in treating infections in critically ill patients
Syamhanin Adnan, David L Paterson, Jeffrey Lipman, et al.
The Lancet. Infectious Diseases
|
February 27, 2026
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance - Authors' reply
David L Paterson, Abdullah T Aslan, Patrick N A Harris
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 29, 2025
The win ratio should be complemented by other win statistics to provide a comprehensive picture of relative and absolute treatment effects: the case study of the REPRIEVE trial
Melissa J Hardy, Sean W X Ong, David L Paterson
Expert Opinion on Drug Metabolism & Toxicology
|
July 20, 2010
Pharmacokinetic evaluation of piperacillin-tazobactam
Yoshiro Hayashi, Jason A Roberts, David L Paterson, et al.
Page
of 58
Search research articles
Search
Showing results (101-110 of 574) with videos related to
Sort By:
Page
of 58
Journal of Clinical Microbiology
|
November 28, 2014
A case of IMP-4-, OXA-421-, OXA-96-, and CARB-2-producing Acinetobacter pittii sequence type 119 in Australia
Witchuda Kamolvit, Petra Derrington, David L Paterson, et al.
The Journal of Antimicrobial Chemotherapy
|
December 17, 2020
An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa
Burcu Isler, Patrick Harris, Adam G Stewart, et al.
Infectious Diseases (London, England)
|
March 6, 2024
Host response signature trends in bacteraemia - authors' response
Anna Maria Peri, Patrick N A Harris, David L Paterson
Antimicrobial Agents and Chemotherapy
|
October 17, 2018
New Treatment Options against Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infections
Burcu Isler, Yohei Doi, Robert A Bonomo, et al.
The American Journal of Tropical Medicine and Hygiene
|
October 14, 2005
Leptospirosis after recreational exposure to water in the Yaeyama islands, Japan
Masashi Narita, Shigeki Fujitani, David A Haake, et al.
Critical Care Medicine
|
July 4, 2008
Antibiotic resistance--what's dosing got to do with it?
Jason A Roberts, Peter Kruger, David L Paterson, et al.
International Journal of Antimicrobial Agents
|
September 18, 2013
Ampicillin/sulbactam: its potential use in treating infections in critically ill patients
Syamhanin Adnan, David L Paterson, Jeffrey Lipman, et al.
The Lancet. Infectious Diseases
|
February 27, 2026
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance - Authors' reply
David L Paterson, Abdullah T Aslan, Patrick N A Harris
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 29, 2025
The win ratio should be complemented by other win statistics to provide a comprehensive picture of relative and absolute treatment effects: the case study of the REPRIEVE trial
Melissa J Hardy, Sean W X Ong, David L Paterson
Expert Opinion on Drug Metabolism & Toxicology
|
July 20, 2010
Pharmacokinetic evaluation of piperacillin-tazobactam
Yoshiro Hayashi, Jason A Roberts, David L Paterson, et al.
Page
of 58